{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:21:11Z","timestamp":1792092071062,"version":"4.4.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T00:00:00Z","timestamp":1670284800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ejmech.2022.114770","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T02:10:30Z","timestamp":1663121430000},"page":"114770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen"],"prefix":"10.1016","volume":"243","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8481-7613","authenticated-orcid":false,"given":"Guillem","family":"Loren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-4947","authenticated-orcid":false,"given":"Irene","family":"Espuny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6056-0566","authenticated-orcid":false,"given":"Alicia","family":"Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3370-6443","authenticated-orcid":false,"given":"Craig","family":"Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9229-969X","authenticated-orcid":false,"given":"Xavier","family":"Verdaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6473-2858","authenticated-orcid":false,"given":"Roger R.","family":"Gomis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-7675","authenticated-orcid":false,"given":"Antoni","family":"Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114770_bib1a","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1152\/physrev.2001.81.4.1535","article-title":"Mechanisms of estrogen action","volume":"81","author":"Nilsson","year":"2001","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2022.114770_bib1b","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.beem.2015.04.008","article-title":"Estrogen receptor alpha and beta in health and disease","volume":"29","author":"Jia","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.ejmech.2022.114770_bib2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2174\/092986713804999303","article-title":"Treatment of estrogen receptor-positive breast cancer","volume":"20","author":"Lumachi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/212733b0","article-title":"Preparation and identification of cis and trans isomers of a substituted triarylethylene","volume":"212","author":"Bedford","year":"1966","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114770_bib4a","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/156802606776173483","article-title":"Estrogen receptors as therapeutic targets in breast cancer","volume":"6","author":"Ariazi","year":"2006","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib4b","series-title":"Nucl. Recept. As Drug Targets","first-page":"127","article-title":"Estrogen receptors as therapeutic targets in breast cancer","author":"Ariazi","year":"2008"},{"key":"10.1016\/j.ejmech.2022.114770_bib5","first-page":"155","article-title":"Antiestrogens: mechanism of action and effects in breast cancer","volume":"vol. 2","author":"Horwitz","year":"1978"},{"key":"10.1016\/j.ejmech.2022.114770_bib6","first-page":"4837","article-title":"Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment","volume":"51","author":"Lien","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114770_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/carcin\/15.4.589","article-title":"A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes","volume":"15","author":"Lim","year":"1994","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2022.114770_bib8","series-title":"World Cancer Report 2014","author":"Stewart","year":"2014"},{"key":"10.1016\/j.ejmech.2022.114770_bib9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.molcel.2005.04.014","article-title":"Structural basis for an unexpected mode of SERM-Mediated ER antagonism","volume":"18","author":"Wu","year":"2005","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114770_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1758834017711097","article-title":"Fulvestrant in advanced breast cancer: evidence to date and place in therapy","volume":"9","author":"Bo\u00e9r","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ejmech.2022.114770_bib11a","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1210\/en.2018-01095","article-title":"Next-generation ER\u03b1 inhibitors for endocrine-resistant ER+ breast cancer","volume":"160","author":"Fanning","year":"2019","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2022.114770_bib10b","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/CCO.0000000000000567","article-title":"Selective oestrogen receptor degraders in breast cancer: a review and perspectives","volume":"31","author":"Gombos","year":"2019","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114770_bib12a","doi-asserted-by":"crossref","first-page":"11301","DOI":"10.1021\/acs.jmedchem.9b01580","article-title":"Design and synthesis of basic selective estrogen receptor degraders for endocrine therapy resistant breast cancer","volume":"62","author":"Lu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib12b","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acs.jmedchem.9b01293","article-title":"Discovery of 6-(2,4-dichlorophenyl)-5-[4-[(3 S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7 H-benzo[7]annulene-2-carboxylic acid (SAR439859), a potent and selective estrogen receptor degrader (SERD) for the treatment of estrogen-receptor-Po","volume":"63","author":"El-Ahmad","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib13","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114770_bib14a","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114770_bib14b","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114770_bib15","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.apsb.2019.08.001","article-title":"Degradation of proteins by PROTACs and other strategies","volume":"10","author":"Wang","year":"2020","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.ejmech.2022.114770_bib16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.chembiol.2020.07.020","article-title":"PROTACs: an emerging therapeutic modality in precision medicine","volume":"27","author":"Nalawansha","year":"2020","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114770_bib17","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1074\/mcp.T300009-MCP200","article-title":"Development of protacs to target cancer-promoting proteins for ubiquitination and degradation","volume":"2","author":"Sakamoto","year":"2003","journal-title":"Mol. Cell. Proteomics"},{"key":"10.1016\/j.ejmech.2022.114770_bib18a","doi-asserted-by":"crossref","first-page":"12436","DOI":"10.1073\/pnas.96.22.12436","article-title":"Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex","volume":"96","author":"Iwai","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114770_bib18b","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1021\/jm5011258","article-title":"Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von hippel-lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in vitro nanomolar affinities","volume":"57","author":"Galdeano","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib18c","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/acs.jmedchem.7b00675","article-title":"Group-based optimization of potent and cell-active inhibitors of the von Hippel\u2013lindau (VHL) E3 ubiquitin ligase: structure\u2013activity relationships leading to the chemical probe (2 S ,4 R)-1-((S)-2-(1-Cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-","volume":"61","author":"Soares","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib19","doi-asserted-by":"crossref","first-page":"7201","DOI":"10.1038\/onc.2008.320","article-title":"Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer","volume":"27","author":"Rodriguez-Gonzalez","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2022.114770_bib20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.bmcl.2003.11.042","article-title":"Degradation of target protein in living cells by small-molecule proteolysis inducer","volume":"14","author":"Zhang","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114770_bib21","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1016\/j.bmcl.2005.04.008","article-title":"Use of PROTACS as molecular probes of angiogenesis","volume":"15","author":"Bargagna-Mohan","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114770_bib22a","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1039\/C0MB00074D","article-title":"Impact of linker length on the activity of PROTACs","volume":"7","author":"Cyrus","year":"2011","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.ejmech.2022.114770_bib22b","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cmdc.201000146","article-title":"Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs","volume":"5","author":"Cyrus","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114770_bib23","series-title":"Proteolysis Targeting Chimeras (Protacs) Directed to the Modulation of the Estrogen Receptor","author":"Campos","year":"2014"},{"key":"10.1016\/j.ejmech.2022.114770_bib24","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cbic.201000222","article-title":"Two-headed PROTAC: an effective new tool for targeted protein degradation","volume":"11","author":"Cyrus","year":"2010","journal-title":"Chembiochem"},{"key":"10.1016\/j.ejmech.2022.114770_bib25","doi-asserted-by":"crossref","first-page":"6768","DOI":"10.1016\/j.bmc.2011.09.041","article-title":"Design, synthesis and biological evaluation of nuclear receptor-degradation inducers","volume":"19","author":"Itoh","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib26a","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.bmcl.2011.11.086","article-title":"Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy","volume":"22","author":"Demizu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114770_bib26b","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/cas.12272","article-title":"Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells","volume":"104","author":"Okuhira","year":"2013","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2022.114770_bib27","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1074\/jbc.RA117.001091","article-title":"Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor \u03b1 degradation","volume":"293","author":"Ohoka","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bcp.2012.04.023","article-title":"Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells","volume":"84","author":"Chen","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114770_bib29a","series-title":"Proteolysis Targeting Chimeras (Protacs) Directed to the Modulation of the Estrogen Receptor","author":"Campos","year":"2014"},{"key":"10.1016\/j.ejmech.2022.114770_bib29b","series-title":"IAP E3 Ligase Directed Proteolysis Targeting Chimeric Molecules","author":"Harling","year":"2016"},{"key":"10.1016\/j.ejmech.2022.114770_bib30","series-title":"Compounds and Their Use in Treating Cancer","author":"Yang","year":"2019"},{"key":"10.1016\/j.ejmech.2022.114770_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114770_bib32a","series-title":"Preparation of Estrogen-Related Receptor Alpha Based PROTAC Compounds and Associated Methods of Use","author":"Crew","year":"2016"},{"key":"10.1016\/j.ejmech.2022.114770_bib32b","series-title":"Preparation of Indole Derivatives as Estrogen Receptor Degraders","author":"Crew","year":"2018"},{"key":"10.1016\/j.ejmech.2022.114770_bib32c","series-title":"Tetrahydronaphthalene and Tetrahydroisoquinoline Derivatives as Estrogen Receptor Degraders and Their Preparation","author":"Crew","year":"2018"},{"key":"10.1016\/j.ejmech.2022.114770_bib33","series-title":"Preparation of Hydroxyproline Analogs for Degradation of Estrogen Receptor Alpha and Their Use for Treating Positive Breast Cancer","author":"Fan","year":"2018"},{"key":"10.1016\/j.ejmech.2022.114770_bib34","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)","volume":"62","author":"Hu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2019.126907","article-title":"Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ER\u03b1)","volume":"30","author":"Dragovich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114770_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112689","article-title":"Targeting estrogen receptor \u03b1 for degradation with PROTACs: a promising approach to overcome endocrine resistance","volume":"206","author":"Lin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112451","article-title":"Optimal linker length for small molecule PROTACs that selectively target p38\u03b1 and p38\u03b2 for degradation","volume":"201","author":"Donoghue","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib38","doi-asserted-by":"crossref","first-page":"9588","DOI":"10.1021\/ja0302836","article-title":"A potent and highly selective inhibitor of human \u03b1-1,3-fucosyltransferase via click chemistry","volume":"125","author":"Lee","year":"2003","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114770_bib39","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S0092-8674(00)81717-1","article-title":"The structural basis of estrogen receptor\/coactivator recognition and the antagonism of this interaction by tamoxifen","volume":"95","author":"Shiau","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114770_bib40","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1021\/jo00133a030","article-title":"Synthesis of the (E) and (Z) isomers of the antiestrogen tamoxifen and its metabolite, hydroxytamoxifen, in tritium-labeled form","volume":"47","author":"Robertson","year":"1982","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114770_bib42","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on Bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system","volume":"14","author":"Dou","year":"2014","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2022.114770_bib43","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1021\/acschembio.9b00092","article-title":"SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate","volume":"14","author":"Roy","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114770_bib44","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114770_bib45","doi-asserted-by":"crossref","first-page":"10878","DOI":"10.1021\/acs.jmedchem.1c00103","article-title":"Discovery of highly potent and selective IRAK1 degraders to probe scaffolding functions of IRAK1 in ABC DLBCL","volume":"64","author":"Fu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114770_bib46","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1016\/j.tet.2010.04.053","article-title":"Efficient tetrahydropyranyl and tetrahydrofuranyl protection\/deprotection of alcohols and phenols with Al(OTf)3 as catalyst","volume":"66","author":"Williams","year":"2010","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2022.114770_bib47","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1021\/acschembio.8b00693","article-title":"Homo-PROTACs for the chemical knockdown of cereblon","volume":"13","author":"Steinebach","year":"2018","journal-title":"ACS Chem. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422006729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422006729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:47:59Z","timestamp":1759330079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422006729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":59,"alternative-id":["S0223523422006729"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114770","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2022-39b7b","asserted-by":"object"}]},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and optimization of oestrogen receptor PROTACs based on 4-hydroxytamoxifen","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114770"}}